FY2024 EPS Estimates for Adlai Nortye Ltd. Raised by Analyst (NASDAQ:ANL)

Adlai Nortye Ltd. (NASDAQ:ANL) – Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for shares of Adlai Nortye in a note issued to investors on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($2.41) for the year, up from their prior forecast of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.

Adlai Nortye Price Performance

Shares of NASDAQ ANL opened at $13.75 on Thursday. The business has a 50 day simple moving average of $9.45 and a 200 day simple moving average of $9.33. Adlai Nortye has a 52 week low of $7.11 and a 52 week high of $19.30.

Institutional Investors Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its stake in shares of Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the SEC. Institutional investors own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.